紫外分光光度法测定甲磺酸酚妥拉明分散片的含量

目的：建立了用紫外分光光度法测定甲磺酸酚妥拉明分散片含量的方法。方法：以０．１ｍｏｌ．Ｌ＾－１盐酸溶液为溶剂,测定波长为２７８ｎｍ。结果：检测线性范围９．６～２８．７μｇ．ｍｌ＾－１,ｒ＝０．９９９８,平均回收率为１００．６％,ＲＥＤ为０．２４％。结论：本方准确、快速、简便,可用于甲磺酸酚妥拉明分散片的质量控制。     

差示分光光度法测定扑麻滴鼻液中马来酸氯苯那敏的含量

目的：测定扑麻滴鼻液中马来酸氯苯那敏的含量,为该药提供质量控制方法。方法：应用差示分光光度法测定扑麻滴鼻液中马来酸氯苯那敏的含量。结果：马来酸氯苯建敏的线性范围１５￣７５μｇ·ｍｌ＾－１。回归方程Ｙ＝０．０１０１８＋０．００５９（ｒ＝０．９９９９）,平均回收率和ＲＳＤ分别为１００．１３％;０．７６％。结论：方法简便、快速、准确,可作为;可作为该制剂的质量控制方法。     

HPLC法测定盐酸普鲁卡因注射液中分解产物对氨基苯甲酸含量

目的：研究和测定盐酸普鲁卡因注射液中的降解产物对氨基甲酸,方法：采用离子对ＨＰＬＣ法,固定相Ｌｕｎａ５μＣ１８（２）柱,流动相为缓冲液（０．００５ｍｏｌ．Ｌ＾－１磷酸二氢钾,ｐＨ３．０,０．１％庚烷磺酸钠）－甲醇（７７：２３）;流速１．５ｍｌ／ｍｉｎ,柱温３５℃;检测波长２８７ｎｍ,结果：对氨基苯酸浓度在２．０～２０．０μｇ．ｍｌ＾－１范围,线性关系良好,回归方程为Ｃ＝５．８０４１×１０＾－５＋０．０７８２９,ｒ ＝０．９９９９。回收率为１００．２％,ＲＳＤ＝０．３２％,结论：本测定方法简便快速,结果准确,可用于该制剂有关物质检查。     

高效液相色谱法测定复方西咪替丁胶囊中西咪替丁的含量

目的：建立高效液相色谱法测定复方西咪替丁胶囊的含量。方法：外标峰面积法。结果：在进样量５ ～２０μｇ·ｍｌ－１范围内有良好的线性关系,标准曲线回归方程为：Ｙ＝１８２ ０１９．９８Ｘ－ ９６７ ．８,ｒ ＝ ０．９９９ ２ 。结论：本法可用于测定复方西咪替丁胶囊中西咪替丁的含量     

薄层扫描法测定扶正抗癌颗粒中黄芪甲甙的含量

目的：测定扶正抗癌颗粒中黄芪甲甙的含量。方法：双波长薄层扫描法,波长λｓ＝５３０ｎｍ ,λＲ＝ ７００ｎｍ 。结果：黄芪甲甙含量线性范围为０．９９６～４．９８μｇ·ｍｌ－１ ,ｒ ＝０ ．９９９ ２,样品加样回收率为９７．２１％ ,ＲＳＤ为２．２１％ 。结论：建立的含量测定方法简便、准确、重现性好     

高效液相色谱法测定退烧冲剂中黄芩苷的含量

目的：测定退烧冲剂中黄芩苷的含量。方法：采用ＨＰＬＣ法,Ｃ１８ 柱,流动相醋酸缓冲液（ｐＨ４．５）－ 甲醇（１∶１）,检测波长２５４ｎｍ 。结果：黄芩苷在０．５～１０ｍｇ·Ｌ－１ 浓度范围内线性关系良好,ｒ ＝ ０．９９９８,平均回收率９８．６％ , ＲＳＤ 为１．５９％ 。结论：所建立的含量测定方法简便、准确,可作为该产品的质量控制方法。     

高效液相色谱法测定痛风灵贴剂中盐酸小檗碱的含量

目的：采用反相高效液相色谱法，测定痛风灵贴剂中盐酸小檗碱的含量。方法：色谱条件为，流动相：甲醇－ ０．４ｍｏｌ·Ｌ－１ 硝酸铵（５２∶４８） ，检测波长３４８ｎｍ 。结果：样品萃取回收率９９．１４ ％ ，加样回收率９８．８３％ ，日内日间ＲＳＤ％ 分别为４．２ ％（ ｎ ＝１２） 和３ ．６ ％（ ｎ ＝９） 。测定３ 批痛风灵贴剂的含量，在０．８５１５～１ ．１０３５ｍｇ·ｇ－１ 范围。结论：本文方法可用于痛风灵贴剂的质量控制     

紫外分光光度法测定盐酸丁卡因胶浆中盐酸丁卡因的含量

目的：建立测定盐酸丁卡因胶浆中盐酸丁卡因含量的方法。方法：采用紫外分光光度法。结果：盐酸丁卡因的线性范围为５ ～１０μｇ·ｍｌ－１ ,Ａ＝０ ．０７５１２Ｃ＋ ０．００３７１,ｒ ＝１．０００ ０。结论：此方法简便、快速、经济、准确、适用于药品质量控制。     

生物体内一氧化氮水平的定量检测研究

目的：为寻求特异性强、灵敏度高的一氧化氮测定方法,解决体内一氧化氮测定的难题。方法：用Ｎ－ 甲基－ Ｄ－葡糖胺二硫代甲酸铁［（ＭＧＤ）２Ｆｅ２＋］ 作为一氧化氮的自旋捕集剂,对小鼠肝、心、肾和肺脏中一氧化氮水平进行电子自旋共振（ＥＳＲ） 测量。结果：对１－０μｍｏｌ·Ｌ－ １的一氧化氮水平,用自旋捕集方法可得到明显的ＥＳＲ信号;对生物组织可测到１－０×１０－ ９ｍｏｌ·ｍｇ－１ 的一氧化氮。结论：为生物体系原位一氧化氮的检测提供了一个高度灵敏和特异性方法     

差示双波长法测定复方酮康唑乳膏中酮康唑的含量

目的：建立新的复方酮康唑乳膏的含量测定方法。方法：改进撮针以波长紫外分光光度法和差示紫外分光光度法结合起来测定酮康唑含量。结果：得到标准曲线Ｃ（ｍｇ．Ｌ＾－１）＝４８．３０９△Ａ－０．２４６４,（ｒ＝０．９９９９）。平均回收率为９８．５１％,ＲＳＤ为１．２４％。结论：该方法重现性好,操作简便,可用于复方酮康唑乳膏的质量控制。     

Knee injury and Osteoarthritis Outcome Score (KOOS) - validation of a Swedish version

The Knee injury and Osteoarthritis Outcome Score (KOOS) is a self-administered instrument measuring outcome after knee injury at impairment, disability, and handicap level in five subscales. Reliability, validity, and responsiveness of a Swedish version was assessed in 142 patients who underwent arthroscopy because of injury to the menisci, anterior cruciate ligament, or cartilage of the knee. The clinimetric properties were found to be good and comparable to the American version of the KOOS. Comparison to the Short Form-36 and the Lysholm knee scoring scale revealed expected correlations and construct validity. Item by item, symptoms and functional limitations were compared between diagnostic groups. High responsiveness was found three months after arthroscopic partial meniscectomy for all subscales but Activities of Daily Living.     

Endovascular management of carotid-cavernous fistulas

Objective To investigate endovascular treatment of traumatic direct carotid-cavernous fistulas （CCF） and their complications such as pseudoaneurysms. Methods： Over a five-year period, 22 patients with traumatic direct CCFs were treated endovascularly in our institution. Thirteen patients were treated once with the result of CCF occluded, 8 twice and 1 three times. Treatment modalities included balloon occlusion of the CCF, sacrifice of the ipsilateral internal carotid artery with detachable balloon, coll embolization of the cavernous sinus and secondary pseudoaneurysms, and covered-stem management of the pseudoaneurysms. Results All the direct CCFs were successfully managed endovascularly. Four patients developed a pseudoaneurysm after the occlusion of the CCF with an incidence of pseudoaneurysm formation of 18.2% （4/22）. A total number of 8 patients experienced permanent occlusion of the ICA with a rate of ICA occlusion reaching 36.4% （8/22）. Followed up through telephone consultation from 6 months to 5 years, all did well with no recurrence of CCF symptoms and signs. Conclusion Traumatic direct CCFs can be successfully managed with endovascular means. The pseudoaneurysms secondary to the occlusion of the CCFs can be occluded with stent-assisted coiling and implantation of covered stents.     

The acutely limping child

Acute limping may be the result of multiple pathologies in children. The differential diagnosis varies based on the age of the child. Irrespective of age, the initial imaging work-up includes AP and frog leg radiographs of the pelvis and ultrasound; MRI may sometimes be helpful. In children less than 3 years, infections and trauma are most frequent. MRI is the imaging modality of choice when osteomyelitis is clinically suspected. Between the ages of 3 and 10 years, transient synovitis of the hip and Legg-Calvé-Perthes disease are main considerations but infection, inflammation and focal bony lesions are also considered. In children over 10 years, slipped capital femoral epiphysis also is considered.     

Do Balance Board Training Programs Reduce the Risk of Ankle Sprains in Athletes?

Introduction Ankle sprains are the most common musculo-skeletal injury that occurs in athletes,particularly in sports that require jumping and landing on one foot such as soccer,and basketball(1-4).These injuries often result in significant time loss from participation,long-term disability,and have a major impact on health care costs and resources(5-8).     

High Intensity Interval Training:New Insights

KEY POINTS ·High-intensity interval training(HIT)is characterized by repeated sessions of relatively brief，intermittent exercise.often performed with an“a11 out”effort or at an intensity close to that which elicits peak oxygen uptake(i.e.，≥90%of VO2 peak).     

Developmental validation of the PowerPlex(®) ESI 16 and PowerPlex(®) ESI 17 Systems: STR multiplexes for the new European standard

In response to the ENFSI and EDNAP groups’ call for new STR multiplexes for Europe, Promega^® developed a suite of four new DNA profiling kits. This paper describes the developmental validation study performed on the PowerPlex^® ESI 16 (European Standard Investigator 16) and the PowerPlex^® ESI 17 Systems. The PowerPlex^® ESI 16 System combines the 11 loci compatible with the UK National DNA Database^®, contained within the AmpFlSTR^® SGM Plus^® PCR Amplification Kit, with five additional loci: D2S441, D10S1248, D22S1045, D1S1656 and D12S391. The multiplex was designed to reduce the amplicon size of the loci found in the AmpFlSTR^® SGM Plus^® kit. This design facilitates increased robustness and amplification success for the loci used in the national DNA databases created in many countries, when analyzing degraded DNA samples. The PowerPlex^® ESI 17 System amplifies the same loci as the PowerPlex^® ESI 16 System, but with the addition of a primer pair for the SE33 locus. Tests were designed to address the developmental validation guidelines issued by the Scientific Working Group on DNA Analysis Methods (SWGDAM), and those of the DNA Advisory Board (DAB). Samples processed include DNA mixtures, PCR reactions spiked with inhibitors, a sensitivity series, and 306 United Kingdom donor samples to determine concordance with data generated with the AmpFlSTR^® SGM Plus^® kit. Allele frequencies from 242 white Caucasian samples collected in the United Kingdom are also presented. The PowerPlex^® ESI 16 and ESI 17 Systems are robust and sensitive tools, suitable for the analysis of forensic DNA samples. Full profiles were routinely observed with 62.5 pg of a fully heterozygous single source DNA template. This high level of sensitivity was found to impact on mixture analyses, where 54–86% of unique minor contributor alleles were routinely observed in a 1:19 mixture ratio. Improved sensitivity combined with the robustness afforded by smaller amplicons has substantially improved the quantity of data obtained from degraded samples, and the improved chemistry confers exceptional tolerance to high levels of laboratory prepared inhibitors.